From Development to Commercial Production

Drug Substance Manufacturing

BioDuro provides an end-to-end drug substance manufacturing network spanning regulatory starting materials, advanced intermediates, GMP kilo lab production, and late-stage commercial API manufacturing.

Facilities in Shanghai, Bengbu, and Taiwan provide the scale, technical expertise, and quality oversight needed to support programs as development and supply requirements evolve.

Manufacturing Across Every Stage

Drug substance manufacturing needs change as a program moves from early development into clinical and commercial production. BioDuro brings together process development, technology transfer, kilo lab production, and large-scale manufacturing to help maintain continuity as programs advance.

RSM & Intermediate Manufacturing

BioDuro’s Bengbu facility supports large-scale production of regulatory starting materials and advanced intermediates, providing a reliable foundation for downstream API manufacturing.

  • 130,000 L total reactor volume
  • 6 pilot-scale production lines
  • 2 commercial-scale production lines

GMP API Kilo Lab

Shanghai-based kilo lab operations connect process development with GMP production, supporting rapid and compliant scale-up for Phase I and Phase II programs.

  • 9 GMP kilo lab reactors
  • 6 production lines with Class D clean rooms
  • Integration from R&D through kilo lab production

Late-Stage Commercial GMP API

Through BioDuro’s joint venture with Cenra API Solutions, the Taiwan facility supports late-stage clinical and commercial cGMP API manufacturing.

  • 8 GMP production lines
  • 2 pilot-scale anbd 6 commercial-scale lines
  • 356,000 L total reactor volume
  • Up to 200 tons maximum annual single-line production

Global Manufacturing Network

Drug substance manufacturing activities are supported by facilities across Shanghai, Bengbu, and Taiwan, providing the infrastructure needed to support programs from early development through commercial production.

Shanghai

Bridging R&D and GMP kilo lab production, with dedicated production lines and GMP reactors supporting Phase I–II scale-up.

Bengbu

Large-scale manufacturing of regulatory starting materials (RSMs) and advanced intermediates with pilot and commercial production capabilities.

Taiwan

Late-stage and commercial API manufacturing supported by extensive production capacity and a strong regulatory inspection history.

Quality & Regulatory Experience

Consistent quality standards across manufacturing sites help simplify scale-up and technology transfer activities. Facilities have undergone inspections by major global regulatory authorities, including the FDA, EMA, NMPA, TGA, PMDA, MFDS, ANSM, and others.

Quality and Regulatory Experience

Aligned quality standards across the manufacturing network help support technology transfer, scale-up, and consistent execution as programs move between sites.

Since 2020, the Shanghai site has completed 10 regulatory inspections by global authorities, including the FDA, EMA, NMPA, and TGA.

The Taiwan facility has completed four FDA cGMP system inspections and has undergone product-specific inspections by global authorities, including the FDA, PMDA, MFDS, ANSM, COFEPRIS, and German regulatory authorities.

An Integrated Manufacturing Network

BioDuro’s drug substance manufacturing network provides a connected path from starting materials and intermediates through kilo lab production and commercial API supply.

Coordination among process development, analytical, quality, and manufacturing teams helps preserve process knowledge, simplify technology transfer, and prepare programs for each new stage of development.